GENE ONLINE|News &
Opinion
Blog

2021-07-30| Asia-Pacific

Takeda Signs New Deal with PeptiDream Spending Billions to Develop Neuromuscular Disease Drugs

by Kathy Huang
Share To

Neuromuscular diseases affect muscle and nerve functions in varying degrees, and the disease progression is primarily unstoppable. As a result, many drugmakers focusing on neurosciences have evolved in recent years. Takeda is one such company that holds neuromuscular diseases as a key strategic area for its growth.

On July 27th, the Japanese pharma giant announced its collaboration with PeptiDream to develop peptide drugs for neuromuscular diseases. According to the agreement, Peptiment will receive an undisclosed upfront payment and milestone payments from Takeda worth up to $3.5 billion.

 

Expanding Takeda-PeptiDream Collaboration

The main obstacle in developing neuroscience drugs is to transfer them into patients’ brains or neural systems. Last December, Takeda and PeptiDream initiated a collaboration to advance peptide-drug conjugates (PDCs) targeting central nervous system diseases to overcome the barrier.

PeptiDream’s proprietary TfR1 binding technology is a novel peptide-drug conjugator for neuromuscular diseases. Takeda uses the TfR1 binding peptide ligands to transport its neural disease drugs across the blood-brain barrier. The tech is an improvement of existing transferring techniques, wherein it can reach the neuromuscular junction that lies beyond the protection of the blood-brain barrier. Also, it promotes enhanced tissue distribution of the drugs.

 

Takeda’s Recent Investments into Neuroscience

Takeda has actively expanded its neuroscience pipelines over the past months. In March, it secured global rights to treatments for rare diseases, Dravet Syndrome and Lennox-Gastaut Syndrome from Ovid Therapeutics. The investigational treatment, soticlestat, was originally discovered at Takeda’s research center.

In the same month, Takeda entered a five-program collaboration with BridGene Biosciences to discover small molecule drugs for undruggable neurodegenerative diseases. The deal is potentially worth more than $500 million.

Related article: Takeda to Pursue Hard-to-Drug Neurodegenerative Disease Targets with BridGene Biosciences

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Study Identifies Bacterial Invasion as a Risk Factor for Brain Implant Longevity
2025-03-19
Study Finds Dopamine Alters Perception of Reward-Linked Memories
2025-03-16
Virtual Nature Scenes Reduce Pain Perception and Alter Brain Activity
2025-03-16
LATEST
AACR Annual Meeting 2025: Cancer Research Innovations, NIH Funding Advocacy, and AI-Driven Advances
2025-04-28
Senti Biosciences to Showcase New Cell & GeneTherapy Data at AACR Annual Meeting 2025
2025-04-27
World Vaccine Congress Washington 2025 Recap: Urgent Calls for Trust, Tech, and Global Access
2025-04-25
Astellas’ Transformation Journey: From Merger to Global Player, Betting on the Edge of Innovation and Risk?
2025-04-25
Roche Announces Massive 50 Billion Dollar Investment in the United States
2025-04-25
Steminent Stands Ready to Showcase Novel MSC-based Therapy for Spinocerebellar Ataxia at Global Stage
2025-04-24
Arkansas Medicaid Work Requirements Led to Coverage Loss for a Significant Number of Recipients
2025-04-24
EVENT
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-05-03
29th Taiwan Joint Cancer Conference 2025
Taipei, Taiwan
2025-05-05
Swiss Biotech Day 2025
Basel, Switzerland
2025-05-13
ASGCT 28th Annual Meeting 2025
New Orleans, U.S.A.
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
Scroll to Top